PL3634419T3 - Obejmujący antagonistę hormonu uwalniającego gonadotropinę reżim dawkowania do stosowania w leczeniu mięśniaków macicy i zmniejszaniu utraty krwi menstruacyjnej - Google Patents

Obejmujący antagonistę hormonu uwalniającego gonadotropinę reżim dawkowania do stosowania w leczeniu mięśniaków macicy i zmniejszaniu utraty krwi menstruacyjnej

Info

Publication number
PL3634419T3
PL3634419T3 PL18731976.9T PL18731976T PL3634419T3 PL 3634419 T3 PL3634419 T3 PL 3634419T3 PL 18731976 T PL18731976 T PL 18731976T PL 3634419 T3 PL3634419 T3 PL 3634419T3
Authority
PL
Poland
Prior art keywords
gonadotropin
dosing regimen
releasing hormone
blood loss
menstrual blood
Prior art date
Application number
PL18731976.9T
Other languages
English (en)
Polish (pl)
Inventor
Ernest Loumaye
Jean-Pierre Gotteland
Oliver Pohl
Original Assignee
Kissei Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co., Ltd. filed Critical Kissei Pharmaceutical Co., Ltd.
Publication of PL3634419T3 publication Critical patent/PL3634419T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL18731976.9T 2017-06-05 2018-06-05 Obejmujący antagonistę hormonu uwalniającego gonadotropinę reżim dawkowania do stosowania w leczeniu mięśniaków macicy i zmniejszaniu utraty krwi menstruacyjnej PL3634419T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515232P 2017-06-05 2017-06-05
PCT/EP2018/064767 WO2018224497A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss

Publications (1)

Publication Number Publication Date
PL3634419T3 true PL3634419T3 (pl) 2025-06-09

Family

ID=62636157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18731976.9T PL3634419T3 (pl) 2017-06-05 2018-06-05 Obejmujący antagonistę hormonu uwalniającego gonadotropinę reżim dawkowania do stosowania w leczeniu mięśniaków macicy i zmniejszaniu utraty krwi menstruacyjnej

Country Status (18)

Country Link
US (2) US11759464B2 (https=)
EP (2) EP3634419B1 (https=)
JP (2) JP7292566B2 (https=)
KR (1) KR102884301B1 (https=)
CN (1) CN110996957A (https=)
AU (2) AU2018280741B2 (https=)
CA (1) CA3066188A1 (https=)
DK (1) DK3634419T3 (https=)
EA (1) EA201992812A1 (https=)
ES (1) ES3018358T3 (https=)
FI (1) FI3634419T3 (https=)
HR (1) HRP20250390T1 (https=)
HU (1) HUE070907T2 (https=)
MX (2) MX2019014482A (https=)
PL (1) PL3634419T3 (https=)
PT (1) PT3634419T (https=)
SG (1) SG11201911599XA (https=)
WO (1) WO2018224497A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
SG11202104053TA (en) * 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
CN114466665A (zh) * 2019-08-08 2022-05-10 奥布赛瓦股份公司 用于治疗雌激素依赖性病症的组合物和方法
AU2020325721A1 (en) * 2019-08-08 2022-03-03 ObsEva S.A. GnRH antagonists for the treatment of estrogen-dependent disorders
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用
KR102738115B1 (ko) 2024-03-25 2024-12-05 한상왕 자궁근종 예방, 개선 또는 치료용 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
KR101384132B1 (ko) 2005-10-19 2014-04-10 깃세이 야쿠힌 고교 가부시키가이샤 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
SG183243A1 (en) * 2010-02-10 2012-09-27 Kissei Pharmaceutical Salt of fused heterocyclic derivative and crystal thereof
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
US10881659B2 (en) * 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
TWI746613B (zh) 2016-08-08 2021-11-21 日商橘生藥品工業股份有限公司 子宮內膜病症治療劑之用法及用量
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders

Also Published As

Publication number Publication date
EP4509173A3 (en) 2025-06-04
EP3634419B1 (en) 2025-01-29
JP2023078315A (ja) 2023-06-06
CA3066188A1 (en) 2018-12-13
KR20200024797A (ko) 2020-03-09
EP4509173A2 (en) 2025-02-19
HRP20250390T1 (hr) 2025-05-23
CN110996957A (zh) 2020-04-10
MX2019014482A (es) 2020-08-17
SG11201911599XA (en) 2020-01-30
PT3634419T (pt) 2025-04-04
AU2018280741A1 (en) 2020-01-30
JP2020522525A (ja) 2020-07-30
AU2024201694A1 (en) 2024-04-04
KR102884301B1 (ko) 2025-11-11
WO2018224497A1 (en) 2018-12-13
ES3018358T3 (es) 2025-05-16
HUE070907T2 (hu) 2025-07-28
FI3634419T3 (fi) 2025-05-02
US20200179390A1 (en) 2020-06-11
JP7292566B2 (ja) 2023-06-19
MX2023013582A (es) 2024-04-16
JP7485815B2 (ja) 2024-05-16
EP3634419A1 (en) 2020-04-15
US11759464B2 (en) 2023-09-19
US20240000785A1 (en) 2024-01-04
AU2018280741B2 (en) 2023-12-21
EA201992812A1 (ru) 2020-05-21
DK3634419T3 (da) 2025-03-31

Similar Documents

Publication Publication Date Title
PL3634419T3 (pl) Obejmujący antagonistę hormonu uwalniającego gonadotropinę reżim dawkowania do stosowania w leczeniu mięśniaków macicy i zmniejszaniu utraty krwi menstruacyjnej
SG11202105797TA (en) Postpartum uterine hemorrhage device
HUS2200027I1 (hu) Esztetrol komponenst tartalmazó, szájban diszpergálódó adagolási egység
PT3270957T (pt) Novo complexo que compreende um péptido de penetração celular, uma carga e um agonista peptídico de tlr para o tratamento de glioblastoma
SG11201911598WA (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
HUE072130T2 (hu) Orális rögzített dózisú kombináció és annak felhasználása méhmióma és endometriosis kezelésében
IL280592A (en) Devices and methods for vaginal treatments
ZA201704958B (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
IL257132A (en) Feminine pad with blocking pleats
IL239791A0 (en) A pharmaceutical formulation containing an insoluble corticosteroid and a soluble corticosteroid
IL259329B (en) A process for preparing a dry powder formulation containing an anticholinergic, corticosteroid, and adrenergic agent
ZA201900777B (en) Usage and dosage of therapeutic agents for endometriosis
IL272864A (en) A therapeutic agent containing an IL-33 antagonist for the treatment of endometriosis
GB201404798D0 (en) Method and device for determining the hydration state of a human or animal body
IL259327B (en) A process for the preparation of a dry powder formulation containing an anticholinergic, corticosteroid and adrenergic agent
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
EP3258858A4 (en) IMPROVED BELT TOLERANT FOR THE TREATMENT OF HEMORRHOIDS AND LOADING DEVICE
SG11202012889QA (en) Dosing regimens for treating hypoxia-associated tissue damage
ZA201803010B (en) Plasminogen dosage regimen for wound healing
IL291196A (en) Standards and methods for determining the dose of the drug
IL254593A0 (en) Combination dosage form of mu opioid receptor antagonist and opioid agent
HK40027582A (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis